Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14800428 | 0.90 | TNIK (0.40) | FFAR1FFAR4MAOBERBB2EGFR | |
| SCHEMBL14818895 | 0.90 | TNIK (0.40) | FFAR1FFAR4METERBB2EGFR | |
| SCHEMBL14804136 | 0.86 | FFAR1 (0.44) | FFAR1FFAR4MAOBMAOAALDH1A1 | |
| SCHEMBL31667435 | 0.77 | MIF (0.53) | ALDH1A1L3MBTL1METMIF | |
| SCHEMBL14801382 | 0.74 | TNIK (0.42) | FFAR1FFAR4ALDH1A1ERBB2EGFR | |
| SCHEMBL14800725 | 0.74 | MAPT (0.45) | MAOBERBB2EGFRARTNIK | |
| SCHEMBL14800038 | 0.71 | MIF (0.44) | ALDH1A1MIFTNIK | |
| SCHEMBL32686737 | 0.70 | NPC1 (0.40) | ALDH1A1METMIFTNIK | |
| SCHEMBL32686754 | 0.70 | NPC1 (0.43) | ALDH1A1METMIFTNIK | |
| SCHEMBL18189848 | 0.69 | NPC1 (0.52) | ALDH1A1METMIFTNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841301-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130079338-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079338-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | FFAR1 415/4885FFAR4 704/4885MAOB 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.